Millrace Asset Group Inc. Trims Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Millrace Asset Group Inc. decreased its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 20.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 166,042 shares of the company’s stock after selling 42,296 shares during the quarter. Millrace Asset Group Inc.’s holdings in MiMedx Group were worth $981,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC lifted its position in shares of MiMedx Group by 8.5% in the first quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock valued at $160,000 after acquiring an additional 1,631 shares in the last quarter. Shell Asset Management Co. bought a new stake in MiMedx Group during the 1st quarter valued at approximately $113,000. Price T Rowe Associates Inc. MD lifted its holdings in MiMedx Group by 13.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock worth $254,000 after purchasing an additional 3,806 shares in the last quarter. Harbor Capital Advisors Inc. bought a new position in MiMedx Group in the 2nd quarter worth approximately $1,781,000. Finally, Bank of New York Mellon Corp grew its holdings in MiMedx Group by 9.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 409,344 shares of the company’s stock valued at $2,837,000 after buying an additional 35,107 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Trading Down 1.2 %

Shares of MDXG opened at $9.09 on Tuesday. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.49. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company’s fifty day moving average is $6.66 and its 200 day moving average is $6.85. The stock has a market capitalization of $1.34 billion, a PE ratio of 16.53 and a beta of 1.94.

Analyst Upgrades and Downgrades

MDXG has been the topic of several research analyst reports. Craig Hallum lowered their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price objective on shares of MiMedx Group in a research report on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.